$47.62−1.18 (−2.42%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Enliven Therapeutics (ELVN) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld. Worth your attention in FY25: Share count (+59.4%) and Capex step-up ($158.0K). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▼16.5%
−103.7
FY21→FY25CAGR —
Free cash flow ($M)▲3.8%
−70.5
capex stepped upCAGR —
Diluted EPS▲3.2%
−1.83
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+59.4%
35.5mn → 56.7mn diluted shares since FY23. Rising share count dilutes EPS. Growth must outrun it.
Capex step-up
$158.0K
▲259% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
Margin trend · direction beats level
This filer reports no gross profit or operating income line, so those margins are not drawn.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.7266, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Research & development | 98,952.0 | 85,856.0 | 80,778.0 | 64,574.0 | 31,022.0 | 38,442.0 | ▲6.3% | +22.2% |
Selling, general & admin | 36,410.0 | 33,802.0 | 23,776.0 | 18,955.0 | 7,769.0 | 13,000.0 | ▲42.2% | +27.0% |
Total operating expenses | 135,362.0 | 119,658.0 | 104,554.0 | 83,529.0 | 38,791.0 | 51,442.0 | ▲14.4% | +23.5% |
Operating incomefeeds ROC rank | −135,362.0 | −119,658.0 | −104,554.0 | −83,529.0 | −38,791.0 | −51,442.0 | ▼14.4% | — |
Other income, net | 21,880.0 | 15,964.0 | 14,889.0 | 11,945.0 | 1,129.0 | 58.0 | — | — |
Pretax income | −113,482.0 | −103,694.0 | −89,665.0 | −71,584.0 | −37,662.0 | −51,384.0 | ▼15.6% | — |
Income tax | — | 0.0 | 232.0 | 0.0 | — | 0.0 | — | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −113,482.0 | −103,694.0 | −89,024.0 | −71,584.0 | −37,662.0 | −51,384.0 | ▼16.5% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −1.68 | −1.83 | −1.89 | −2.01 | −12.05 | −2.37 | ▲3.2% | — |
Diluted shares (mn) | 77.98 | 56.66 | 47.07 | 35.55 | 3.12 | 21.66 | ▲20.4% | +27.2% |
| Margins | ||||||||
† TTM = trailing four quarters through 2026-09-30.
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-03 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

